Role of non-HLA antibodies in organ transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 4, 2012, Pages 440-445

  Dragun, Duska ^a   Philippe, Aurélie ^a   Catar, Rusan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

angiotensin type 1 receptor antibodies; antibody mediated rejection; anticollagen V antibodies; antiendothelial cell antibodies; MICA antibodies

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

BRONCHIOLITIS OBLITERANS; CAPILLARITIS; CARDIAC ALLOGRAFT VASCULOPATHY; CHRONIC GRAFT REJECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULITIS; GLOMERULOPATHY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; INTERMEDIATE FILAMENT; KIDNEY ALLOGRAFT; KIDNEY FAILURE; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; PLASMAPHERESIS; PREECLAMPSIA; REVIEW; SYSTEMIC SCLEROSIS;

ANTIBODIES; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; INTERMEDIATE FILAMENTS; ORGAN TRANSPLANTATION; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84863826332     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328355f12b     Document Type: Review

References (42)

1. Praprotnik S, Blank M, Meroni PL, et al. Classification of antiendothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. Arthritis Rheum 2001; 44:1484-1494.
2. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100:158-173.
3. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007; 100:174-190.
4. Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating antiendothelial cell antibodies rather than preexisting antibodies is associated with posttransplant allograft rejection. Kidney Int 2011; 79:655-662.
5. Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87:549-556.
6. Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 2011; 92: 54-60.
7. Le Bas-Bernardet S, Hourmant M, Coupel S, et al. Non-HLA-type endothelial cell reactive alloantibodies in pretransplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003; 3:167-177.
8. Canet E, Devalliere J, Gerard N, et al. Profiling posttransplant circulating antibodies in kidney transplantation using donor endothelial cells. Transplantation 2012; 93:257-264.
9. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1994; 91:6259-6263.
10. Zou Y, Stastny P. Role of MICA in the immune response to transplants. Tissue Antigens 2010; 76:171-176.
11. Zou Y, Stastny P, Susal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293-1300.
12. Lemy A, Andrien M, Wissing KM, et al. Major histocompatibility complex class 1 chain-related antigen a antibodies: sensitizing events and impact on renal graft outcomes. Transplantation 2010; 90:168-174.
13. Lemy A, Andrien M, Lionet A, et al. Posttransplant major histocompatibility complex class 1 chain-related gene A antibodies and long-term graft outcomes in a multicenter cohort of 779 kidney transplant recipients. Transplantation 2012. [Epub ahead of print]
14. Smith JD, Brunner VM, Jigjidsuren S, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant 2009; 9:1912-1919.
15. Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: targets of antibodymediated rejection in heart transplantation. Transplantation 2011; 91:1153-1158.
16. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71:886-892.
17. Mizobuchi T, Yasufuku K, Zheng Y, et al. Differential expression of Smad7 transcripts identifies the CD4-CD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 2003; 171:1140-1147.
18. Kalache S, Dinavahi R, Pinney S, et al. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. J Immunol 2011; 187:1023-1030.
19. Nath DS, Tiriveedhi V, Basha HI, et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 2011; 91:1036-1043.
20. Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibodyinduced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant 2010; 15:16-20.
21. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558-569.
22. Riemekasten G, Philippe A, Nather M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70:530-536.
23. Reinsmoen NL, Lai CH, Heidecke H, et al. Antiangiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90:1473-1477.
24. Sis B, Einecke G, Chang J, et al. Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation, and scarring. Am J Transplant 2010; 10:421-430.
25. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibodymediated microcirculation inflammation in kidney transplants. Am J Transplant 2012. 2012; 12:1168-1179.
26. Hiemann NE , Meyer R, Wellnhofer E, et al. Prognostic impact of non-HLA antibodies targeting vascular receptors for the development of microvasculopathy in biopsy after heart transplantation Abstract O95 presented in ESOT (European Society of Organ Transplantation) Congress 2009.
27. Barten MJ, Dieterlen MT, Riede R, et al. Early and higher incidence of cardiac allograft vasculopathy after heart transplantation is linked to non-HLA antibodies; Abstract 128 presented in ATC (American Transplant Congress) 2011.
28. Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 2008; 14:855-862.
29. Porcheray F, DeVito J, Yeap BY, et al. Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. Transplantation 2010; 89:1239-1246.
30. Sutherland SM, Li L, Sigdel TK, et al. Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int 2009; 76:1277-1283.
31. Sigdel TK, Li L, Tran TQ, et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012; 23: 750-763.
32. Dinavahi R, George A, Tretin A, et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol 2011; 22:1168-1178.
33. Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9:998-1005.
34. Billet S, Bardin S, Tacine R, et al. The AT1A receptor gain-of-function mutant N111S/delta329 is both constitutively active and hyperreactive to angiotensin II. Am J Physiol Endocrinol Metab 2006; 290:E840-E848.
35. Billet S, Bardin S, Verp S, et al. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest 2007; 117:1914-1925.
36. Kelsch R, Everding AS, Kuwertz-Broking E, et al. Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. Transplantation 2011; 92:e57-e59.
37. Clatworthy MR, Espeli M, Torpey N, Smith KG. The generation and maintenance of serum alloantibody. Curr Opin Immunol 2010; 22:669-681.
38. Win TS, Pettigrew GJ. Humoral autoimmunity and transplant vasculopathy: when allo is not enough. Transplantation 2010; 90:113-120.
39. Bartel G, Schwaiger E, Bohmig GA. Prevention and treatment of alloantibodymediated kidney transplant rejection. Transpl Int 2011; 24:1142-1155.
40. Jordan SC, Reinsmoen N, Peng A, et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 2010; 25:2035-2045; quiz 2045-2038.
41. Kranz B, Kelsch R, Kuwertz-Broking E, et al. Acute antibody-mediated rejection in paediatric renal transplant recipients. Pediatr Nephrol 2011; 26: 1149-1156.
42. Jackson AM, Kuperman MB, Montgomery RA. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant 2012; 12:1643-1649.